ArticleBlood neoplasia2026
Real-world clinical outcomes in patients with CLL previously treated with covalent BTKi and BCL2i regimens.
Article in Blood neoplasia, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Chronic Lymphocytic Leukemia: Molecular Pathologies and Therapeutic Strategies.International journal of molecular sciences · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Patients with chronic lymphocytic leukemia (CLL) who are double-exposed (DE) or double-refractory (DR) to covalent Bruton tyrosine kinase inhibitors (cBTKi) and B-cell lymphoma 2 inhibitors (BCL2i) have limited treatment options and poor outcomes. We evaluated real-world treatment patterns, response, and time-to-event (TTE) outcomes in patients with DE CLL (N = 264), and among the DE-only (ie, DE but not DR; n =157) and DR (n = 107) subcohorts, using the Flatiron Health Research Database. The DE cohort included patients who started first-line therapy for CLL on/after 1 January 2011, had a line of therapy (LOT) for CLL after being DE and on/before 30 November 2022, and met other inclusion criteria. Real-world response rate (rwRR) and TTE outcomes (duration of response [rwDOR], progression-free survival [rwPFS], time to next treatment [rwTTNT], and overall survival [rwOS]), were evaluated. Most patients were retreated with a cBTKi- and/or a BCL2i-based therapy (DE, 69%; DE only, 75%; DR, 54%) as their first index LOT. rwRR was similar between groups (DE, 39%; DE only, 41%; DR, 36%), but median TTE outcomes were shorter in the DR subcohort (DR vs DE vs DE only: rwDOR, 11.5 vs 20.3 vs 26.2 months; rwPFS, 5.0 vs 8.8 vs 11.3 months; rwTTNT, 8.0 vs 13.8 vs 22.1 months; rwOS, 14.7 vs 25.2 vs 38.2 months) and shorter with each subsequent index LOT. Our results suggest an unmet need among patients with DR CLL. Future studies should continue to evaluate response durability with different treatments in DE and DR CLL populations.
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.